Crossing between biotech and pharma: what transfers, what does not, and how to frame the difference honestly

The move between biotech and pharma is one of the most common pivots experienced Life Sciences professionals consider — and one of the least well-understood. Both worlds develop and commercialize medicines. Both value scientific rigor. Beyond that, the operating assumptions diverge sharply, and candidates who paper over those differences in a resume or interview rarely land well.

This piece is about being honest with yourself and with a prospective employer about what you have actually done, at what scale, and under what constraints — and then framing that experience in a way that is accurate rather than inflated.

What genuinely transfers

Scientific and technical depth transfers almost completely. A medicinal chemist, a regulatory strategist, a clinical operations leader, a biostatistician — the underlying discipline crosses the divide with very little friction. Hiring teams on both sides understand this, and it is rarely the sticking point.

Urgency and ownership also travel well, often in surprising directions. Biotech professionals accustomed to wearing multiple hats bring a bias toward action that larger organizations frequently want to inject into slower-moving functions. Pharma professionals moving to a smaller company bring familiarity with structured process — IND filing discipline, CMC documentation rigor, regional regulatory strategy — that a growing biotech may be building for the first time. Neither is superior; both are genuinely useful, and saying so plainly in an interview is more persuasive than overselling adaptability in the abstract.

Cross-functional fluency transfers, though it looks different at each scale. In a smaller biotech, you may have been the de facto voice of clinical, regulatory, and commercial in a single meeting. In a large pharma organization, those functions have dedicated leadership and you need to influence rather than absorb them. The underlying skill — reading a room, building alignment across disciplines — is the same. The context is not, and conflating them is where candidates lose credibility.

What does not transfer cleanly

Budget authority is the most common gap, and the hardest to frame without sounding either small or inflated. A VP of Clinical Operations at an early-stage biotech may have had direct P&L visibility and vendor relationships that a Director at a large pharma company does not — but the pharma Director may be managing a study portfolio of far greater complexity and geographic reach. Neither description is wrong. The mistake is to equate titles or to obscure the true scope of what you controlled versus what you influenced.

Process infrastructure is another genuine discontinuity. Pharma runs on validated systems, SOPs layered over decades, and governance structures that can feel bureaucratic until you need them. Biotech often builds process in real time, which develops a different kind of judgment. When a pharma hiring team asks whether you have worked within a RACI matrix or a stage-gate review process, they are not asking a trick question — they want to know whether you will need to be taught how the organization works or whether you can step in and operate. Answer accurately.

Stakeholder scale cuts in both directions. A pharma Global Medical Affairs Director may have managed relationships with dozens of internal markets and external advisory boards. A biotech counterpart may have a far tighter network but deeper individual relationships. Neither is a deficit in isolation. The deficit is claiming stakeholder management experience that does not match the actual complexity of what you did.

The most credible candidates are the ones who describe the constraints they worked inside, not just the outcomes they achieved.

How to frame scale differences honestly

The practical advice is simple and frequently ignored: describe the actual parameters of your work before you describe the results. How many countries, how many patients, what budget range, how many direct reports, how many vendors, what stage of development. If those parameters are modest relative to the role you are targeting, say so — and then explain what you built or learned inside those constraints that would apply at larger scale. Hiring managers respect that framing. They are experienced enough to see through the alternative.

On the resume itself, context statements help. A brief phrase that establishes the size and stage of the organization — before the bullet points — gives a reader the frame they need to evaluate your accomplishments accurately. Without it, a reader from a different-scale organization will either over- or under-read what you did.

In interviews, the transition narrative matters as much as the credentials. Be specific about why you are making the move and what you expect to be different. Vague language about wanting a new challenge or broader impact tends to signal that the candidate has not thought carefully about what they are walking into. Specific language — about the structural differences you understand, the skills you are bringing, and the gaps you expect to close — signals preparation and intellectual honesty.

A note on how roles are posted

One practical factor worth knowing: the way Life Sciences roles are described in postings does not always make the biotech-pharma distinction legible. Work mode is increasingly disclosed — across 1,890 postings that stated a work mode, 43% of postings that state a work mode are remote, 42% of postings that state a work mode are hybrid, and 15% of postings that state a work mode are on-site — which tells you something about operational expectations. Compensation is a different story: across a corpus of 10,000 postings, 0% of postings disclose a salary range, which means you are navigating scale and pay expectations largely without data from the posting itself.

That opacity makes the quality of your positioning more important, not less. When you cannot anchor a conversation to a posted range, what you can control is how precisely and credibly you represent what you have done — and why it is relevant to what the organization needs. That is true whether you are moving from a lean biotech into a global pharma company or in the opposite direction. The translation is possible. The work is in being honest about what needs translating.